Diffuse large B cell lymphoma: How can we cure more patients in 2012?

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalBest Practice and Research: Clinical Haematology
Volume25
Issue number1
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Refractory materials
Cells
Scanning
Therapeutics
Rituximab
Positron Emission Tomography Computed Tomography

Keywords

  • cell or origin
  • diffuse large B cell lymphoma
  • double hit lymphoma
  • FDG-PET

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Diffuse large B cell lymphoma : How can we cure more patients in 2012? / Moskowitz, Craig.

In: Best Practice and Research: Clinical Haematology, Vol. 25, No. 1, 01.03.2012, p. 41-47.

Research output: Contribution to journalReview article

@article{4d758c4a715e461595576448741e5e49,
title = "Diffuse large B cell lymphoma: How can we cure more patients in 2012?",
abstract = "Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.",
keywords = "cell or origin, diffuse large B cell lymphoma, double hit lymphoma, FDG-PET",
author = "Craig Moskowitz",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.beha.2012.01.008",
language = "English (US)",
volume = "25",
pages = "41--47",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Diffuse large B cell lymphoma

T2 - How can we cure more patients in 2012?

AU - Moskowitz, Craig

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.

AB - Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.

KW - cell or origin

KW - diffuse large B cell lymphoma

KW - double hit lymphoma

KW - FDG-PET

UR - http://www.scopus.com/inward/record.url?scp=84858315205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858315205&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2012.01.008

DO - 10.1016/j.beha.2012.01.008

M3 - Review article

C2 - 22409822

AN - SCOPUS:84858315205

VL - 25

SP - 41

EP - 47

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 1

ER -